Recapping The First Two Days Of ASHP Summer Meetings 2023
What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?
Novel ADHD Therapy More Tolerable, Less Effective Than Current Treatment Options
Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor.
CGRP Inhibitors Significantly Reduce Disability in Migraine
Study results add to the body of evidence demonstrating the efficacy of CGRP inhibitors for migraine treatment and prophylaxis.
Why Are Pharmacogenomics Not Fully Implemented in Health Care?
A look at how the genetics-based research field can become more fully integrated in all areas of health care going forward.
Optimizing Oncology Drug Interaction Alerts to Improve Patient Safety
Although excessive use can lead to fatigue, alerts can help proactively identify and prevent drug interactions.
ASHP: Adalimumab Biosimilar Pipeline Review
At least 6 adalimumab biosimilars are set to launch in July 2023.
Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.
